Nuevozen and FTDC partner to develop AI powered Breast Cancer Diagnostic & risk prediction solution
By: Nuevozen Corp
The Bahamas ranks among the top 20 countries in the world in terms of the number of women per capita with breast cancer. The breast cancer incidence rate (IR) for females in the Bahamas is increasing and 48% of the Bahamian patients diagnosed with breast cancer are less than 50 year of age and are diagnosed at Stage III. Three different genes influencing breast cancer have been identified in Bahamian women making it a country with one of the highest proportion of mutations in the world, and approximately 24 percent of the women with breast cancer in The Bahamas have one of these mutations. There are also many other risks factors that are still not well understood.
Fourth Terrace Diagnostic Centre's founder, CEO and Lead Radiologist, Dr. C. Elizabeth Darville MBBS, FRCP, has been at the forefront of cancer care in Bahamas for more than 35 years. She has promoted screening from earlier ages for Bahamian women and has seen the benefit of early diagnosis for her patients.
"If Nuevozen's AI solution can assist our radiologists in improving breast cancer diagnosis, we can improve patient outcome through early detection" said Dr. Darville, "Also if an AI solution is able to predict individual Bahamian women's risk of developing breast cancer, we will be able to move from age-based screening to risk-based screening, and this will dramatically improve early detection and survival." "We are pleased to announce that Dr. Vijay Anand Subramanian, who has been a part of our team for many years, has been appointed as the Director of our Artificial Intelligence Research and Development Department.
Fourth Terrace Diagnostic Centre's President, Mr. Stanley Darville explained that, "Technological advances in medicine continue to occur at almost an exponential pace and Fourth Terrace Diagnostic Centre is working closely with our local Bahamian IT firm Redstone Technologies to provide the high level of support for our data Centre and the immense computing power that is needed to implement Nuevozen's Artificial Intelligence solution."
"We are extremely excited to be working with FTDC." said Karan Aujla, co-founder and CEO of Nuevozen, "Current risk models are population-based and these risk models don't apply to Bahamian women due to the high incidence of genetic mutations, and available data has shown that by using the genetic information together with and the information available in the DICOM images and the patient history, we can come up with a more accurate risk assessment. I believe that by analyzing patient data using AI techniques we can help healthcare providers in improving prevention and treatment of breast cancer."